|
CN104761637B
(zh)
|
2006-03-31 |
2021-10-15 |
中外制药株式会社 |
调控抗体血液动力学的方法
|
|
US8080248B2
(en)
|
2006-06-02 |
2011-12-20 |
Regeneron Pharmaceuticals, Inc. |
Method of treating rheumatoid arthritis with an IL-6R antibody
|
|
JP5307708B2
(ja)
|
2006-06-02 |
2013-10-02 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ヒトｉｌ−６受容体に対する高親和性抗体
|
|
CN101563365B
(zh)
|
2006-08-03 |
2012-10-31 |
瓦西尼斯公司 |
抗-il-6单克隆抗体及其用途
|
|
TW200831528A
(en)
|
2006-11-30 |
2008-08-01 |
Astrazeneca Ab |
Compounds
|
|
WO2009010539A2
(en)
*
|
2007-07-19 |
2009-01-22 |
Ablynx. N.V. |
Receptor for interleukin-6 (il-6) from macaca fascicularis
|
|
KR101680906B1
(ko)
|
2007-09-26 |
2016-11-30 |
추가이 세이야쿠 가부시키가이샤 |
항체 정상영역 개변체
|
|
ES2595638T3
(es)
|
2007-09-26 |
2017-01-02 |
Chugai Seiyaku Kabushiki Kaisha |
Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
|
|
JP2009092508A
(ja)
*
|
2007-10-09 |
2009-04-30 |
Norihiro Nishimoto |
リウマチ治療剤の効果の予測方法
|
|
KR102057826B1
(ko)
|
2008-04-11 |
2019-12-20 |
추가이 세이야쿠 가부시키가이샤 |
복수 분자의 항원에 반복 결합하는 항원 결합 분자
|
|
MX2010012031A
(es)
|
2008-05-13 |
2011-01-20 |
Novimmune Sa |
Anticuerpos anti-il-6/il-6r y metodos de uso de los mismos.
|
|
TWI440469B
(zh)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
|
CN102271705A
(zh)
|
2008-12-22 |
2011-12-07 |
墨尔本大学 |
骨关节炎治疗
|
|
EP2826789A1
(en)
|
2009-03-19 |
2015-01-21 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
|
WO2010106812A1
(en)
*
|
2009-03-19 |
2010-09-23 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical formulation containing improved antibody molecules
|
|
JP5717624B2
(ja)
|
2009-03-19 |
2015-05-13 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
JO3417B1
(ar)
|
2010-01-08 |
2019-10-20 |
Regeneron Pharma |
الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
|
|
AR080428A1
(es)
|
2010-01-20 |
2012-04-11 |
Chugai Pharmaceutical Co Ltd |
Formulaciones liquidas estabilizadas contentivas de anticuerpos
|
|
EP2647706B1
(en)
|
2010-11-30 |
2023-05-17 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
|
|
SG192117A1
(en)
|
2011-01-28 |
2013-08-30 |
Sanofi Sa |
Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
|
|
MX341578B
(es)
*
|
2011-02-08 |
2016-08-25 |
Abbvie Inc |
Tratamiento de la osteoartritis y del dolor.
|
|
MX352889B
(es)
|
2011-02-25 |
2017-12-13 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo de fc especifico para fcyriib.
|
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
|
JP6322411B2
(ja)
|
2011-09-30 |
2018-05-09 |
中外製薬株式会社 |
複数の生理活性を有する抗原の消失を促進する抗原結合分子
|
|
TWI589299B
(zh)
|
2011-10-11 |
2017-07-01 |
再生元醫藥公司 |
用於治療類風濕性關節炎之組成物及其使用方法
|
|
KR20230143201A
(ko)
|
2011-11-30 |
2023-10-11 |
추가이 세이야쿠 가부시키가이샤 |
면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
|
|
US10782290B2
(en)
|
2013-06-11 |
2020-09-22 |
National Center Of Neurology And Psychiatry |
Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
|
|
CN118105480A
(zh)
|
2013-11-12 |
2024-05-31 |
赛诺菲生物技术公司 |
用于与pcsk9抑制剂一起使用的给药方案
|
|
US9017678B1
(en)
|
2014-07-15 |
2015-04-28 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
|
EP3194025A4
(en)
*
|
2014-09-18 |
2018-05-23 |
Rush University Medical Center |
Methods for preventing or treating osteoarthritis
|
|
KR101860280B1
(ko)
|
2014-12-19 |
2018-05-21 |
추가이 세이야쿠 가부시키가이샤 |
항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
|
|
BR112017011235A2
(pt)
|
2014-12-19 |
2018-02-06 |
Chugai Pharmaceutical Co Ltd |
anticorpos anti-c5 e métodos de uso
|
|
KR102605798B1
(ko)
|
2015-02-05 |
2023-11-23 |
추가이 세이야쿠 가부시키가이샤 |
이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
|
|
CA2972393A1
(en)
|
2015-02-27 |
2016-09-01 |
Chugai Seiyaku Kabushiki Kaisha |
Composition for treating il-6-related diseases
|
|
US10697883B2
(en)
|
2015-05-19 |
2020-06-30 |
National Center Of Neurology And Psychiatry |
Method for determining application of therapy to multiple sclerosis (MS) patient
|
|
CA2991637C
(en)
|
2015-07-31 |
2022-07-05 |
Medimmune Limited |
Methods for treating hepcidin-mediated disorders
|
|
JP2018523684A
(ja)
|
2015-08-18 |
2018-08-23 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
|
|
WO2017110981A1
(en)
|
2015-12-25 |
2017-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-myostatin antibodies and methods of use
|
|
EP3494991A4
(en)
|
2016-08-05 |
2020-07-29 |
Chugai Seiyaku Kabushiki Kaisha |
COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES
|
|
WO2018139623A1
(en)
|
2017-01-30 |
2018-08-02 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-sclerostin antibodies and methods of use
|
|
KR20200012823A
(ko)
|
2017-02-01 |
2020-02-05 |
예일 유니버시티 |
이뇨제 내성의 치료
|
|
WO2018203545A1
(ja)
|
2017-05-02 |
2018-11-08 |
国立研究開発法人国立精神・神経医療研究センター |
Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
|
|
JP7235249B2
(ja)
|
2017-10-20 |
2023-03-08 |
学校法人兵庫医科大学 |
抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
|
|
EP3735421A4
(en)
|
2018-01-05 |
2021-09-22 |
Corvidia Therapeutics, Inc. |
METHOD OF TREATMENT OF IL-6 MEDIATED INFLAMMATION WITHOUT IMMUNSUPPRESSION
|
|
WO2019151418A1
(ja)
|
2018-01-31 |
2019-08-08 |
元一 加藤 |
Ｉｌ－６阻害剤を含有する喘息の治療剤
|
|
MA54861A
(fr)
|
2019-01-31 |
2021-12-08 |
Regeneron Pharma |
Anticorps anti-récepteur de l'il6 pour traiter l'arthrite idiopathique juvénile
|
|
EP3957324A4
(en)
|
2019-04-17 |
2023-02-08 |
Hiroshima University |
THERAPEUTIC FOR UROLOGICAL ONCOLOGY CHARACTERIZED BY BEING ADMINISTRATED IN COMBINATION WITH IL-6 INHIBITOR AND CCR2 INHIBITOR
|
|
SG11202111742QA
(en)
|
2019-04-24 |
2021-11-29 |
Sanofi Biotechnology |
Methods of diagnosis and treatment of rheumatoid arthritis
|
|
CA3142710A1
(en)
|
2019-06-04 |
2020-12-10 |
Sanofi Biotechnology |
Compositions and methods for treating pain in subjects with rheumatoid arthritis
|
|
WO2021067749A2
(en)
*
|
2019-10-02 |
2021-04-08 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for the treatment of osteoarthritis
|
|
EP4159236A4
(en)
|
2020-05-29 |
2024-08-21 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody-containing formulation
|